Andreas Pfutzner

Summary

Affiliation: Institute for Clinical Research and Development
Country: Germany

Publications

  1. ncbi Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 6:910-6. 2012
  2. ncbi Clinical assessment of the accuracy of blood glucose measurement devices
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Curr Med Res Opin 28:525-31. 2012
  3. ncbi Self-assessment and objective determination of dexterity in patients with type 1 or type 2 diabetes mellitus
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Curr Med Res Opin 28:15-21. 2012
  4. ncbi Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the
    Markolf Hanefeld
    GWT TUD mbH, Fiedlerstr 34, 01307 Dresden, Germany
    Cardiovasc Diabetol 10:65. 2011
  5. ncbi Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 12:599-604. 2010
  6. ncbi Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism
    Andreas Pfutzner
    Institute for Clinical Research and Development, Parcusstr 8, D 55116 Mainz, Germany
    Expert Opin Drug Deliv 2:1097-106. 2005
  7. ncbi Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Metabolism 55:20-5. 2006
  8. ncbi High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus
    Andreas Pfutzner
    University of Applied Sciences, Rheinbach, Germany
    Diabetes Technol Ther 8:28-36. 2006
  9. ncbi Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality
    Andreas Pfutzner
    Institut für Klinische Forschung und Entwicklung IKFE, Institute for Clinical Research and Development, Parcusstr 8, D 55116 Mainz, Germany
    Expert Opin Pharmacother 7:463-76. 2006
  10. ncbi Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
    Andreas Pfutzner
    Institute for Clinical Research and Development, IKFE GmbH, Parcusstrasse 8, 55116 Mainz, Germany
    Clin Chem Lab Med 44:556-60. 2006

Collaborators

Detail Information

Publications77

  1. ncbi Comparison of patient preference for two insulin injection pen devices in relation to patient dexterity skills
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 6:910-6. 2012
    ..This study was performed to investigate the impact of dexterity impairment on patient preference for two insulin pen injection devices (InnoLet and FlexTouch)...
  2. ncbi Clinical assessment of the accuracy of blood glucose measurement devices
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Curr Med Res Opin 28:525-31. 2012
    ..BGStar and iBGStar are employ dynamic electrochemistry, which is supposed to result in highly accurate results...
  3. ncbi Self-assessment and objective determination of dexterity in patients with type 1 or type 2 diabetes mellitus
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Curr Med Res Opin 28:15-21. 2012
    ....
  4. ncbi Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the
    Markolf Hanefeld
    GWT TUD mbH, Fiedlerstr 34, 01307 Dresden, Germany
    Cardiovasc Diabetol 10:65. 2011
    ..We analyzed specific effects of an add-on therapy with pioglitazone compared to metformin and their combination in patients with basal insulin treatment on biomarkers of CV risk...
  5. ncbi Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 12:599-604. 2010
    ....
  6. ncbi Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism
    Andreas Pfutzner
    Institute for Clinical Research and Development, Parcusstr 8, D 55116 Mainz, Germany
    Expert Opin Drug Deliv 2:1097-106. 2005
    ..Provided a reliable long-term safety profile, TI may become a suitable alternative to subcutaneous injection for prandial insulin delivery. TI offers the possibility of new treatment regimens, especially in patients with Type 2 diabetes...
  7. ncbi Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Metabolism 55:20-5. 2006
    ..In conclusion, our short-term investigation of rosiglitazone action provides further experimental support for the rationale of combining rosiglitazone with sulfonylurea drugs in patients with type 2 diabetes...
  8. ncbi High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus
    Andreas Pfutzner
    University of Applied Sciences, Rheinbach, Germany
    Diabetes Technol Ther 8:28-36. 2006
    ..Positive results in these trials will further strengthen the value and acceptance of hsCRP, which is recommended as a predictive laboratory marker for cardiovascular disease risk also in patients with diabetes mellitus...
  9. ncbi Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality
    Andreas Pfutzner
    Institut für Klinische Forschung und Entwicklung IKFE, Institute for Clinical Research and Development, Parcusstr 8, D 55116 Mainz, Germany
    Expert Opin Pharmacother 7:463-76. 2006
    ..Because of its additional microvascular and macrovascular effects, pioglitazone is an attractive and effective treatment option for the management of Type 2 diabetes mellitus...
  10. ncbi Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
    Andreas Pfutzner
    Institute for Clinical Research and Development, IKFE GmbH, Parcusstrasse 8, 55116 Mainz, Germany
    Clin Chem Lab Med 44:556-60. 2006
    ..Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP)...
  11. ncbi The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus
    Andreas Pfutzner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 8:375-84. 2006
    ..Supplementary insulin therapy provides assistance to meal-time insulin secretion in patients with type 2 diabetes and may have protective effects on beta-cell function...
  12. ncbi FlexPen for the delivery of insulin: accuracy, injection force and patient preference
    Andreas Pfutzner
    Pfützner Institute for Clinical Research and Development, Mainz, Germany
    Expert Rev Med Devices 6:115-23. 2009
    ..Current evidence suggests that FlexPen and Next Generation FlexPen are an attractive choice when considering insulin-delivery methods...
  13. ncbi High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone
    Andreas Pfutzner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 4:706-16. 2010
    ....
  14. ncbi Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Parcusstr 8 D 55116 Mainz, Germany
    Expert Rev Cardiovasc Ther 4:445-59. 2006
    ..These results underline the value of pioglitazone for managing the increased cardiovascular risk of patients with a metabolic syndrome or Type 2 diabetes mellitus...
  15. ncbi A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Clin Lab 54:485-90. 2008
    ....
  16. ncbi Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Vasc Health Risk Manag 3:211-20. 2007
    ..The purpose of this review is to evaluate the clinical data that have been published on this combination, appearing to represent a convenient way to obtain therapeutic targets in patients with type 2 diabetes mellitus...
  17. ncbi Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Expert Opin Pharmacother 8:1985-98. 2007
    ..They underline the value of this drug when used alone or in combination with other antidiabetic drugs for a successful management of Type 2 diabetes mellitus...
  18. ncbi Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Clin Lab 55:275-81. 2009
    ..We evaluated the plausibility of results derived from a new ELISA (Immundiagnostik, Bensheim, Germany) in comparison to a different ELISA test (Mercodia, Uppsala, Sweden)...
  19. ncbi PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 13:637-43. 2011
    ..The aim of our study was to investigate the effect of a fixed pioglitazone + metformin (PM) combination (vs. glimepiride + metformin [GM]) on diabetic dyslipidemia...
  20. ncbi Analysis of the environmental impact of insulin infusion sets based on loss of resources with waste
    Andreas Pfutzner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:843-7. 2011
    ..The loss or resources with regular CSII is considerably lower than the loss or resources induced by patch pumps...
  21. ncbi Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease
    A Pfutzner
    IKFE Institute for Clinical Research and Development Mainz, Germany
    Clin Lab 54:237-41. 2008
    ..Visfatin secretion is not regulated by PPARgamma and further research is required to investigate its role in insulin resistance...
  22. ncbi Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone
    Andreas Pfutzner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:784-93. 2011
    ....
  23. ncbi Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 6:405-12. 2004
    ..Assessment of beta-cell function by determination of intact proinsulin may facilitate the selection of the most promising therapy and may also serve to monitor treatment success in the further course of the disease...
  24. ncbi Evaluation of a new fully automated one-step C-peptide chemiluminescence assay (LIAISON C-Peptid)
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Clin Lab 49:227-32. 2003
    ..In general, the new LIAISON chemiluminescence assay compared favorably with the RIA and comparative chemiluminescence test and offers an attractive alternative for C-peptide analysis...
  25. ncbi [Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus]
    A Pfutzner
    Institut für klinische Forschung und Entwicklung, Mainz D
    Schweiz Med Wochenschr 130:1854-61. 2000
    ..Since the successful development of devices for continuous glucose monitoring, the development of closed-loop systems has become more and more the focus of current clinical and technological research...
  26. ncbi Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Care 27:682-7. 2004
    ..This investigation explored the predictive value of intact proinsulin as an insulin resistance marker...
  27. ncbi Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance
    Andreas Pfutzner
    Institute of Clinical Research and Development, IKFE GmbH, Mainz, Germany
    Clin Lab 49:571-6. 2003
    ..It may, however, be concluded from this study that at least in cross-sectional epidemiological investigations, fasting human resistin concentrations are not significantly correlating with any clinical measure for insulin resistance...
  28. ncbi Comparison of immunoassays for the detection of anti-GAD65 autoantibodies in patients with diabetes mellitus
    A Pfutzner
    Endocrine Research Laboratory ELAB, University Hospital Mainz, Germany
    Clin Lab 46:275-9. 2000
    ..Increased measurement of the diabetes-associated antibodies will be helpful in the differential diagnosis of gestational diabetes mellitus (GDM) and latent autoimmune diabetes of the adult (LADA)...
  29. ncbi Clinical and laboratory evaluation of specific chemiluminescence assays for intact and total proinsulin
    Andreas Pfutzner
    IKFE, Institute of Clinical Research and Development, Mainz, Germany
    Clin Chem Lab Med 41:1234-8. 2003
    ..Both CLIAs could be performed much faster (4 hours) than the RIA method (75 hours/ 4 days). In conclusion, the CLIA methods show improved qualitative outcomes, higher specificity and several technical advantages over the RIA method...
  30. ncbi Pilot study with technosphere/PTH(1-34)--a new approach for effective pulmonary delivery of parathyroid hormone (1-34)
    A Pfutzner
    MannKind Biopharmaceuticals, 1 Casper Street, Danbury, CT, USA
    Horm Metab Res 35:319-23. 2003
    ..In conclusion, pulmonary application of Technosphere/PTH(1 - 34) appears to be an effective and thus attractive candidate for PTH substitution therapy in osteoporosis and other conditions leading to a decrease in bone mineral density...
  31. ncbi Technosphere/Insulin--a new approach for effective delivery of human insulin via the pulmonary route
    Andreas Pfutzner
    Pharmaceutical Discovery Corporation, A MannKind Company, Danbury, Connecticut, USA
    Diabetes Technol Ther 4:589-94. 2002
    ..c. injection for prandial insulin delivery, especially in patients with Type 2 diabetes, if the long-term safety, tolerability, and efficacy of this pulmonary insulin are established and confirmed in future studies...
  32. ncbi Impact of posture and fixation technique on impedance spectroscopy used for continuous and noninvasive glucose monitoring
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 6:435-41. 2004
    ..Well-educated patients might be the best candidates for first using the device for continuous glucose monitoring. They may especially benefit from the trend indication and the hypoglycemia/hyperglycemia threshold and alarm functions...
  33. ncbi Cross-sectional investigation on the accuracy of alternate site glucose testing using the Soft-Sense glucose meter
    Andreas Pfutzner
    Institut für klinische Forschung und Entwicklung, Mainze
    Swiss Med Wkly 132:351-7. 2002
    ....
  34. ncbi Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control
    A Pfutzner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    Horm Metab Res 37:510-5. 2005
    ..Adiponectin, intact proinsulin, and the IRIS-II score may be suitable parameters for monitoring of these additional beneficial therapeutic effects...
  35. ncbi Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin
    A Pfutzner
    University of Applied Sciences, Rheinbach, Germany
    Clin Lab 51:243-9. 2005
    ..sample for HbA1c measurement, is increasing the probability of the acceptance of this marker for routine assessment of beta-cell dysfunction and insulin resistance in type 2 diabetes...
  36. ncbi Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Parcusstrasse 8, D 55116 Mainz, Germany
    J Am Coll Cardiol 45:1925-31. 2005
    ..This study was performed to assess whether the anti-inflammatory and antiatherogenic effects of pioglitazone suggested by animal experiments are reproducible in man and independent from improvements in metabolic control...
  37. ncbi IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design
    Andreas Pfutzner
    University of Applied Sciences, Rheinbach, Germany
    Diabetes Technol Ther 7:478-86. 2005
    ..The cross-sectional IRIS-II study tried to assess the prevalence of insulin resistance and macrovascular disease in orally treated patients with Type 2 diabetes...
  38. ncbi Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:989-98. 2011
    ..This study investigated the effects of pioglitazone (PIO), ramipril (RAM), or their combination (PIRA) on low-grade inflammation in nondiabetic hypertensive patients with increased cardiovascular risk...
  39. ncbi [Pitfalls in the diagnosis and treatment optimization of type 2 diabetes]
    A Pfutzner
    Institut für klinische Forschung und Entwicklung Mainz
    MMW Fortschr Med 147:47-50. 2005
    ..New biochemical markers such as adiponectin and intact proinsulin may facilitate treatment decisions and monitoring in patients with type 2 diabetes...
  40. ncbi [Practical diagnosis in insulin resistance and beta-cell dysfunction and resulting therapeutic consequences]
    A Pfutzner
    Fachhochschule Bonn Rhein Sieg, Rheinbach
    MMW Fortschr Med 146:32-3, 35. 2004
  41. ncbi Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study
    Petra B Musholt
    Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 3:1442-50. 2009
    ..The aim of our study was to examine the efficacy of short-term intravenous insulin intervention followed by oral pioglitazone/metformin therapy to prevent patients from continuous insulin application...
  42. ncbi IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance
    Matthias R Langenfeld
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 6:836-43. 2004
    ....
  43. ncbi Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state
    Clothilde Hohberg
    Institute for Clinical Research and Development, Parcusstrasse 8, D 55116 Mainz, Germany
    Diabetes Care 31:1021-5. 2008
    ..To investigate the effect of insulin glulisine on postprandial microvascular blood flow in type 2 diabetes...
  44. ncbi Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk
    Thomas Forst
    Medical Director, Institute for Clinical Research and Development, Mainz, Germany
    Diab Vasc Dis Res 5:298-303. 2008
    ..05 respectively). Atorvastatin significantly improved IMT and vascular elasticity. Co-administration of pioglitazone provided additional effects on endothelial function, lipid profile and laboratory markers of inflammation...
  45. ncbi Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus
    Thomas Forst
    Institute for Clinical Research and Development, University of Mainz, Germany
    Clin Sci (Lond) 119:345-51. 2010
    ..47; P<0.05). This is the first study showing an improvement in EI during treatment with PIO, which was associated with an increase in adiponectin and a decrease in intact proinsulin levels, but independent of glycaemic control...
  46. ncbi The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study
    Thomas Schondorf
    Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:426-32. 2011
    ..This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin...
  47. ncbi Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study
    Thomas Forst
    Institute for Clinical Research and Development, Medical Department, D 55116 Mainz, Germany
    Metabolism 56:491-6. 2007
    ..05) during PIO/SIM treatment. Lipid parameters improved during SIM treatment but not during PIO treatment. Combined treatment with PIO/SIM was superior in improving overall cardiovascular risk profile than every single drug...
  48. ncbi Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 11:87-92. 2009
    ....
  49. ncbi Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus
    Thomas Schondorf
    Institute of Clinical Research and Development, Mainz, Germany
    Clin Lab 53:193-8. 2007
    ..In women, other pathways may superimpose this effect. In conclusion, our study supports the hypothesis of different regulating pathways and effects of relaxin in men and women also in patients with type 2 diabetes...
  50. ncbi Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Microcirculation 12:543-50. 2005
    ..The study was performed to investigate the effect of improving metabolic control with pioglitazone in comparison to glimepiride on microvascular function in patients with diabetes mellitus type 2...
  51. ncbi Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Care 33:116-20. 2010
    ..This study compared the effect of VIAject with human regular insulin and insulin lispro on postprandial oxidative stress and endothelial function in patients with type 2 diabetes...
  52. ncbi Patient device assessment evaluation of two insulin injection devices in a mixed cohort of insulin-treated patients with type 1 or type 2 diabetes mellitus
    Christina Schipper
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Curr Med Res Opin 28:1297-303. 2012
    ..The aim of this study was to evaluate patient perception of FT versus IL (InnoLet†) with respect to the ease of use and patient preference in a mixed patient cohort with different kinds and degrees of visual or dexterity impairments...
  53. ncbi Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions
    Thomas Schondorf
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 11:379-83. 2009
    ....
  54. ncbi Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes
    Tanja Reimer
    Institute for Clinical Research and Development GmbH, Mainz, Germany
    Clin Ther 30:2252-62. 2008
    ..Because the use of insulin therapy can place a substantial burden on patients with diabetes, insulin administration should be as simple as possible...
  55. ncbi Elevated peripheral visfatin levels in narcoleptic patients
    Norbert Dahmen
    Department of Psychiatry, University of Mainz, Mainz, Germany
    PLoS ONE 3:e2980. 2008
    ..Visfatin is a recently described proinflammatory adipokine. It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF). Our study examines the hypothesis that visfatin levels are altered in narcoleptic patients...
  56. ncbi Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Clin Lab 50:567-73. 2004
    ..Both assays can thus be used to assess beta-cell function, to facilitate the selection of the most promising therapy, and may also serve to monitor treatment success in the further course of the disease...
  57. ncbi Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes
    Thomas Forst
    Institute for Clinical Research and Development, Parcusstrasse 8, Mainz D 55116, Germany
    J Diabetes Complications 19:128-32. 2005
    ..0 (19.0-49.3) vs. 20.9 (9.7-26.1) AU, P=.0001]. Postprandial microvascular blood flow is disturbed in patients with Type 1 diabetes. Improvement of postprandial metabolic control was found to improve postprandial microvascular function...
  58. ncbi Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3
    Volkmar Schmid
    IKFE CRO, Mainz, Germany
    J Diabetes Sci Technol 4:976-82. 2010
    ....
  59. ncbi Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study
    Thomas Schondorf
    Institute for Clinical Research and Development, Mainz, Germany
    Diab Vasc Dis Res 7:145-50. 2010
    ..Patients with diabetes mellitus and IGT have a high risk for cardiovascular events. It is tempting to speculate that these patients are often first seen by cardiologists...
  60. ncbi Development and validation of a rapid and reliable method for TPMT genotyping using real-time PCR
    Marion Lorenz
    Institute for Clinical Research and Development ikfe GmbH, Mainz, Germany
    Clin Lab 58:959-71. 2012
    ..Development of a fast and reliable real-time PCR application for TPMT genotyping would greatly improve thiopurine treatment regimens and allow the avoidance of adverse drug reactions...
  61. ncbi Evaluation of dexterity in insulin-treated patients with type 1 and type 2 diabetes mellitus
    Julia Pfützner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:158-65. 2011
    ..Dexterity skills may play an important role in the performance efficacy of these procedures...
  62. ncbi Pilot study for the evaluation of morphological and functional changes in retinal blood flow in patients with insulin resistance and/or type 2 diabetes mellitus
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 6:163-8. 2012
    ..The aim of this study was to investigate early morphological and functional pathology in the retinal micro-circulation in patients with insulin resistance and/or type 2 diabetes mellitus (T2DM)...
  63. ncbi Determination of nitrotyrosine concentrations in plasma samples of diabetes mellitus patients by four different immunoassays leads to contradictive results and disqualifies the majority of the tests
    Michael Safinowski
    Institute for Clinical Research and Development, Mainz, Germany
    Clin Chem Lab Med 47:483-8. 2009
    ..The peroxynitrite concentrations can be indirectly monitored by the detection of nitrotyrosine residues in proteins, reflecting the extent of damage caused by oxidative stress...
  64. ncbi Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control
    Thomas Forst
    Institute for Clinical Research and Development, 55116 Mainz, Germany
    Exp Diabetes Res 2012:635472. 2012
    ....
  65. ncbi Comparison of the dose accuracy of prefilled insulin pens
    Alexander Weise
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 3:149-53. 2009
    ..This study compared the dosing accuracy of two prefilled insulin pens (the SoloStar((R)) from Sanofi Aventis, Berlin, Germany, and the Next Generation [NG] FlexPen((R)) from Novo Nordisk, Mainz, Germany)...
  66. ncbi Review of approved pioglitazone combinations for type 2 diabetes
    Thomas Forst
    IKFE Institute for Clinical Research and Development, Parcusstr 8, D 5116 Mainz, Germany
    Expert Opin Pharmacother 12:1571-84. 2011
    ..The treating of T2DM patients by addressing not only glucose control, but also the underlying pathophysiological etiology might help to improve patient prognosis in the long run, especially with regard to the vascular complications...
  67. ncbi Development of a high throughput single nucleotide polymorphism screening method for the cytochrome P450 1A2 polymorphisms CYP1A2*1C and CYP1A2*1F: are they useful as predictive markers in mental disorders?
    Marco Klemm
    PharmGenomics GmbH, Mainz, Germany
    Clin Lab 56:473-80. 2010
    ....
  68. ncbi Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery disease
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Research Laboratory, 55116 Mainz, Germany
    PPAR Res 2011:647017. 2011
    ....
  69. ncbi Assessment of the mixing efficiency of neutral protamine Hagedorn cartridges
    Pia Kaiser
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 4:652-7. 2010
    ..All other cartridges with fewer bullets were shown to deliver potentially harmful doses if used for treatment when the mixing procedure was less frequent than demanded in the instructions for use...
  70. ncbi Laboratory evaluation of a new lateral-flow-based point-of-care rapid test for assessment of chronic systemic inflammation
    Renate Siebenhaar
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 4:717-22. 2010
    ..It may therefore be suitable for a fast and convenient screening, which, after laboratory test confirmation, may help to identify patients with elevated risk of macrovascular disease...
  71. ncbi Evaluation of CGMS during rapid blood glucose changes in patients with type 1 diabetes
    Birgit Wilhelm
    Institute for Clinical Research and Development, Johannes Gutenberg University, Mainz, Germany
    Diabetes Technol Ther 8:146-55. 2006
    ..CONCLUSIONS: Continuous glucose measurements using CGMS provide reliable glucose measurements even in the case of dynamic blood glucose changes...
  72. ncbi Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain
    Thomas Forst
    Institute for Clinical Research and Development and Department of Endocrinology, University of Mainz, Mainz, Germany
    Br J Clin Pharmacol 64:75-82. 2007
    ..The purpose of the current study was to establish the safety and maximal tolerated dose of CNS 5161 HCl...
  73. ncbi Dynamic electrochemistry corrects for hematocrit interference on blood glucose determinations with patient self-measurement devices
    Petra B Musholt
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:1167-75. 2011
    ..The purpose of this laboratory investigation was to assess the potential influence of hematocrit variations on a variety of blood glucose meters applying different measurement technologies...
  74. ncbi Peripheral leptin levels in narcoleptic patients
    Norbert Dahmen
    Department of Psychiatry, University of Mainz, Mainz, Germany
    Diabetes Technol Ther 9:348-53. 2007
    ..Two studies have reported decreased leptin levels, whereas a larger, recent study failed to detect differences between patients and controls...
  75. ncbi Evaluation of SET--a new device for the measurement of pain perception in comparison to standard measures of diabetic neuropathy
    Mai Nguyen
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 6:601-6. 2004
    ..82; vibration = 0.61; temperature = 0.42; light touch = 0.11). CONCLUSIONS: Measurement of pain perception threshold using the SET device is an easy and reliable method for identifying patients with impaired small nerve fiber function...
  76. ncbi Biological background and role of adiponectin as marker for insulin resistance and cardiovascular risk
    Thomas Schondorf
    University of Applied Science, Dept of Applied Natural Sciences, Rheinbach, Germany
    Clin Lab 51:489-94. 2005
    ..This review summarizes recent biological and clinical data indicating that adiponectin may be the molecular link between obesity and insulin resistance and may serve as a biomarker for the metabolic syndrome...
  77. ncbi Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide
    Thomas Wallerath
    Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany
    Nitric Oxide 9:95-102. 2003
    ..We suggest that this effect may contribute to the increase in skin and muscle blood flow previously demonstrated in human in vivo...